Cytodyn Inc (CYDY)

[kgromax]

Here you go: the strategically used "modified" keyword. In 2 PLACES THAT ARE CRITICAL. As well as this sentence: "LifeTracDx™ appears to aid as a parallel diagnostic tool in identifying patients that respond to leronlimab"

It's the usual Cytodyn playbook.

They define their own metrics, used nowhere else, which do not represent the full spectrum of cases in a hospital, by which magically they can announce magical results.

Here their metric EXCLUDES patients that did not go well. Nothing magical in observing that the remaining patients have a good outcome.

Investors who believe this are tricked once again, for the 10th time.